Business Context and Reporting Period
Company: Semtech Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 29, 2006 (Third Quarter of Fiscal Year 2007)
Context: This filing is part of a concurrent restatement of financial statements for fiscal years 2002 through 2006 due to incorrect accounting for stock-based compensation. The company is currently under investigation by the SEC and the Department of Justice regarding historical stock option practices. Disclosure controls and procedures were deemed ineffective due to a material weakness in the control environment involving former executives.
Key Financial Metrics
| Metric | Three Months Ended Oct 29, 2006 | Nine Months Ended Oct 29, 2006 |
|---|---|---|
| Net Sales | $63.7 million | $194.6 million |
| Gross Profit | $34.5 million (54.2% margin) | $107.8 million (55.4% margin) |
| Operating Income | $4.6 million | $23.5 million |
| Net Income | $6.4 million | $26.5 million |
| Diluted EPS | $0.09 | $0.36 |
| Cash and Cash Equivalents | $110.1 million | $110.1 million (Balance Sheet) |
| Total Investments | $216.3 million | $216.3 million (Balance Sheet) |
| Long-Term Debt | $0 | $0 |
| Working Capital | $301.0 million | $301.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% year-over-year for the quarter and 11% for the nine-month period. Growth was driven by an 88% increase in sales to industrial, medical, and military markets, partially offset by declines in computer and cellular phone applications.
- Profitability Decline: Operating income decreased 59% for the quarter and 26% for the nine-month period compared to the prior year. This decline was primarily due to a significant increase in operating expenses.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 70% for the quarter. This increase includes approximately $4.9 million in legal, accounting, and tax fees related to the stock option investigation, restatement, and derivative litigation.
- Stock-Based Compensation: The adoption of SFAS 123(R) in Q1 2007 significantly increased stock-based compensation expense compared to prior periods. Additionally, the restatement adjustments added $341,000 in pre-tax expense for the quarter ended Oct 30, 2005.
- Segment Performance: The Standard Semiconductor Products segment saw operating income drop 66% due to investigation costs and lower margins. Conversely, the Rectifier, Assembly and Other Products segment saw operating income rise 234% due to a surge in military and industrial demand.
Guidance, Outlook, Risks, and Unusual Items
- Restatement Impact: The company restated prior periods to record approximately $91.0 million in additional pre-tax non-cash stock-based compensation expense related to options granted between 1996 and 2003. The impact on fiscal year 2007 is immaterial.
- Legal and Regulatory Risks: The company faces ongoing SEC and Grand Jury investigations into stock option practices. Five shareholder derivative lawsuits are pending. The company has incurred substantial legal fees and expects to continue incurring significant expenses.
- Stock Option Exercise Restrictions: During the restatement process, employees were prohibited from exercising stock options. The company authorized cash payments to certain employees for expired options and accrued $2.1 million for other expired options.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective due to a material weakness in the control environment involving the Former CEO and Former CFO. Remediation began with their departure in late 2006.
- Nasdaq Listing: The company faced potential delisting due to late filings but has filed the necessary reports to regain compliance. The Listing Council has stayed the delisting decision pending review.
- Acquisition: The company acquired XEMICS in June 2005. The earn-out period ended in April 2006 with no additional payment required as performance objectives were not met.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the $91.0 million restatement on historical earnings and the timeline for the completion of the restatement process.
- Legal Exposure: Monitor the status of the SEC investigation, Grand Jury subpoena, and shareholder derivative lawsuits for potential penalties or damages.
- Management Turnover: Assess the stability of the new management team and the effectiveness of remediated internal controls following the departure of the Former CEO and CFO.
- Stock Option Liability: Review the $2.1 million accrual for expired options and the potential for additional claims from other optionees.
- Investment Portfolio: Confirm the liquidity and market risk exposure of the $216.3 million investment portfolio, particularly regarding auction rate securities.
- Supply Chain Concentration: Evaluate risks associated with reliance on foreign subcontractors, particularly the third-party foundry in China which supplied 58% of silicon wafers in the prior fiscal year.